NEW YORK

纽约

,

，

June 12, 2026

2026年6月12日

/PRNewswire/ --

/美通社/ --

Transcend Therapeutics

超越疗法公司

today announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (Otsuka), marking a significant milestone in Transcend's mission to develop rapid-acting treatments for neuropsychiatric diseases, including post-traumatic stress disorder (PTSD).

今日宣布完成由大冢美国公司（Otsuka America Inc.，大冢制药株式会社［Otsuka］的子公司）对其的收购，这标志着Transcend在致力于开发包括创伤后应激障碍（PTSD）在内的神经精神疾病快速起效治疗药物的使命中迈出了重要里程碑。

The acquisition was originally .

该收购最初是。

announced

宣布

on March 27, 2026.

2026年3月27日。

With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka America, Inc.

随着交易的完成，Transcend 已成为 Otsuka America, Inc. 的全资子公司。

'Today marks an important milestone for Transcend and people suffering from PTSD,' said Blake Mandell, co-founder and CEO of Transcend Therapeutics. 'In just a few years, our team advanced TSND-201 into Phase 3 clinical development. By joining Otsuka, this work will move forward with greater resources and reach.

“今天对Transcend以及创伤后应激障碍（PTSD）患者而言，标志着一个重要的里程碑。”Transcend Therapeutics联合创始人兼首席执行官Blake Mandell表示。“在短短几年内，我们的团队将TSND-201推进至III期临床开发阶段。通过与大冢制药合作，这项工作将在更丰富的资源和更广泛的影响力支持下持续推进。”

We are incredibly proud of what our team has accomplished and look forward to continuing this work together with Otsuka to bring meaningful new treatment options to patients in need.'.

我们为我们团队所取得的成就感到无比自豪，并期待与大冢继续携手合作，为有需要的患者带来具有临床意义的新治疗选择。

The acquisition follows a period of significant clinical and regulatory progress for Transcend. TSND-201, a rapid-acting neuroplastogen being developed by Transcend, demonstrated favorable results in

此次收购紧随Transcend在临床和监管方面取得重大进展之后。由Transcend开发的快速起效神经塑性生成剂TSND-201展现了良好的结果

IMPACT-1

IMPACT-1

, its Phase 2 clinical trial, with results published in

，其二期临床试验，结果发表于

JAMA Psychiatry

《美国医学会杂志·精神病学》

. In 2025, TSND-201 received FDA

2025年，TSND-201获得美国食品药品监督管理局（FDA）

Breakthrough Therapy Designation

突破性疗法认定

for the PTSD indication, and earlier this year was awarded an FDA

针对创伤后应激障碍（PTSD）适应症，并于今年早些时候获得美国食品药品监督管理局（FDA）

Commissioner's National Priority Voucher

专员国家优先券

, recognizing the program's potential to address a significant unmet need in mental health. A Phase 3 trial with TSND-201 for the treatment of PTSD is currently ongoing.

，认识到该计划在解决心理健康领域重大未满足需求方面的潜力。目前，一项评估TSND-201治疗创伤后应激障碍（PTSD）的III期临床试验正在进行中。

Since its founding in 2021, Transcend has focused on developing rapid-acting treatments for neuropsychiatric disorders, with the goal of addressing significant unmet needs for patients who have not benefited from existing therapies.

自2021年成立以来，Transcend一直致力于开发针对神经精神疾病的快速起效疗法，旨在满足那些未能从现有治疗中获益的患者的重大未竟医疗需求。

'Transcend's innovative approach reflects Otsuka's legacy and commitment to addressing the significant unmet needs in mental health, including PTSD,' said Tarek Rabah, president and CEO, Otsuka North America Pharmaceutical Business. 'Together, we are well positioned to accelerate the development of new neuropsychiatric therapeutic options and bring meaningful innovation to patients.'.

大冢北美制药业务总裁兼首席执行官塔雷克·拉巴赫表示：“Transcend 的创新方法体现了大冢的传统以及致力于解决包括创伤后应激障碍（PTSD）在内的精神健康领域重大未满足需求的承诺。我们携手合作，具备良好优势，能够加速开发新的神经精神疾病治疗选择，为患者带来具有意义的创新。”

About TSND-201

关于 TSND-201

TSND-201 (methylone) is a rapid-acting neuroplastogen developed by Transcend. TSND-201 has well-characterized primary pharmacology, with its primary site of action at the monoamine transporters, and no activity at 5-HT2A receptors (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications.

TSND-201（甲基酮）是由Transcend公司开发的一种快速起效的神经塑性生成剂。TSND-201具有明确的主要药理学特性，其主要作用位点为单胺类转运体，且对5-HT2A受体无活性（即不具有致幻作用）。Transcend正在将TSND-201开发为一种快速起效且疗效持久的创伤后应激障碍（PTSD）及其他中枢神经系统（CNS）适应症的治疗药物。

TSND-201 is an investigational medication..

TSND-201 是一种在研药物。

About Transcend Therapeutics

关于Transcend Therapeutics

Transcend, founded in 2021 and based in New York City, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. The company's mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked.

Transcend 成立于2021年，总部位于纽约市，是一家专注于神经科学的临床阶段公司，致力于开发针对神经精神疾病的快速起效疗法。该公司的使命是为数百万对现有精神类药物无效的患者开发新药。

https://transcendtherapeutics.com/

https://transcendtherapeutics.com/

About Otsuka

关于大冢

Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement.

大冢制药株式会社是一家综合性健康企业，致力于激发每个人的潜能以提升其福祉。我们的医疗相关业务提供针对身心健康的诊疗方案。我们的营养保健品业务则支持日常健康的维护与改善。

Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide..

大冢的独特产品和服务基于科学证据，并在我们企业理念的指导下进行：大冢——为全球更健康的生活创造新产品。

www.otsuka.co.jp/en/

www.otsuka.co.jp/en/

.

。

Contact:

联系方式：

[email protected]

[email protected]

SOURCE Transcend Therapeutics

来源：Transcend Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示